Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2012

01-06-2012 | Review

Energy metabolism and rheumatic diseases: from cell to organism

Authors: Cornelia M Spies, Rainer H Straub, Frank Buttgereit

Published in: Arthritis Research & Therapy | Issue 3/2012

Login to get access

Abstract

In rheumatic and other chronic inflammatory diseases, high amounts of energy for the activated immune system have to be provided and allocated by energy metabolism. In recent time many new insights have been gained into the control of the immune response through metabolic signals. Activation of immune cells as well as reduced nutrient supply and hypoxia in inflamed tissues cause stimulation of glycolysis and other cellular metabolic pathways. However, persistent cellular metabolic signals can promote ongoing chronic inflammation and loss of immune tolerance. On the organism level, the neuroendocrine immune response of the hypothalamic-pituitary adrenal axis and sympathetic nervous system, which is meant to overcome a transient inflammatory episode, can lead to metabolic disease sequelae if chronically activated. We conclude that, on cellular and organism levels, a prolonged energy appeal reaction is an important factor of chronic inflammatory disease etiology.
Appendix
Available only for authorised users
Literature
1.
Buttgereit F, Burmester GR, Brand MD: Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today. 2000, 21: 192-199.CrossRefPubMed
2.
Straub RH, Cutolo M, Buttgereit F, Pongratz G: Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010, 267: 543-560. 10.1111/j.1365-2796.2010.02218.x.CrossRefPubMed
3.
4.
Fox CJ, Hammerman PS, Thompson CB: Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005, 5: 844-852. 10.1038/nri1710.CrossRefPubMed
5.
Mathis D, Shoelson SE: Immunometabolism: an emerging frontier. Nat Rev Immunol. 2011, 11: 81-83. 10.1038/nri2922.CrossRefPubMed
6.
7.
Tannahill GM, O'Neill LA: The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3. FEBS Lett. 2011, 585: 1568-1572. 10.1016/j.febslet.2011.05.008.CrossRefPubMed
8.
Inoki K, Kim J, Guan KL: AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012, 52: 381-400. 10.1146/annurev-pharmtox-010611-134537.CrossRefPubMed
9.
Nutsch K, Hsieh C: When T cells run out of breath: the HIF-1α story. Cell. 2011, 146: 673-674. 10.1016/j.cell.2011.08.018.CrossRefPubMed
10.
11.
Procaccini C, Galgani M, De Rosa V, Matarese G: Intracellular metabolic pathways control immune tolerance. Trends Immunol. 2012, 33: 1-7. 10.1016/j.it.2011.09.002.CrossRefPubMed
12.
Gatza E, Wahl DR, Opipari AW, Sundberg TB, Reddy P, Liu C, Glick GD, Ferrara JL: Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med. 2011, 3: 67ra8-PubMedCentralCrossRefPubMed
13.
Jones RG, Thompson CB: Revving the engine: signal transduction fuels T cell activation. Immunity. 2007, 27: 173-178. 10.1016/j.immuni.2007.07.008.CrossRefPubMed
14.
Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324: 1029-1033. 10.1126/science.1160809.PubMedCentralCrossRefPubMed
15.
Summers SA, Yin VP, Whiteman EL, Garza LA, Cho H, Tuttle RL, Birnbaum MJ: Signaling pathways mediating insulin-stimulated glucose transport. Ann N Y Acad Sci. 1999, 892: 169-186. 10.1111/j.1749-6632.1999.tb07795.x.CrossRefPubMed
16.
Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB: The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002, 16: 769-777. 10.1016/S1074-7613(02)00323-0.CrossRefPubMed
17.
Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC: IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008, 111: 2101-2111. 10.1182/blood-2007-06-096297.PubMedCentralCrossRefPubMed
18.
19.
Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001, 15: 807-826. 10.1101/gad.887201.CrossRefPubMed
20.
Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 2004, 18: 1926-1945. 10.1101/gad.1212704.CrossRefPubMed
21.
Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010, 39: 171-183. 10.1016/j.molcel.2010.06.022.PubMedCentralCrossRefPubMed
22.
Ghillebert R, Swinnen E, Wen J, Vandesteene L, Ramon M, Norga K, Rolland F, Winderickx J: The AMPK/SNF1/SnRK1 fuel gauge and energy regulator: structure, function and regulation. FEBS J. 2011, 278: 3978-3990. 10.1111/j.1742-4658.2011.08315.x.CrossRefPubMed
23.
Hardie DG: AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25: 1895-1908. 10.1101/gad.17420111.PubMedCentralCrossRefPubMed
24.
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008, 30: 214-226. 10.1016/j.molcel.2008.03.003.PubMedCentralCrossRefPubMed
25.
26.
Lamia KA, Sachdeva UM, DiTacchio L, Williams EC, Alvarez JG, Egan DF, Vasquez DS, Juguilon H, Panda S, Shaw RJ, Thompson CB, Evans RM: AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science. 2009, 326: 437-440. 10.1126/science.1172156.PubMedCentralCrossRefPubMed
27.
Dziurla R, Gaber T, Fangradt M, Hahne M, Tripmacher R, Kolar P, Spies CM, Burmester GR, Buttgereit F: Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD4+ T lymphocytes. Immunol Lett. 2010, 131: 97-105. 10.1016/j.imlet.2010.02.008.CrossRefPubMed
28.
Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F: Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!. Ann Rheum Dis. 2005, 64: 971-980. 10.1136/ard.2004.031641.PubMedCentralCrossRefPubMed
29.
Tripmacher R, Gaber T, Dziurla R, Haupl T, Erekul K, Grutzkau A, Tschirschmann M, Scheffold A, Radbruch A, Burmester GR, Buttgereit F: Human CD4+ T cells maintain specific functions even under conditions of extremely restricted ATP production. Eur J Immunol. 2008, 38: 1631-1642. 10.1002/eji.200738047.CrossRefPubMed
30.
Falchuk KH, Goetzl EJ, Kulka JP: Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am J Med. 1970, 49: 223-231. 10.1016/S0002-9343(70)80078-X.CrossRefPubMed
31.
Lund-Olesen K: Oxygen tension in synovial fluids. Arthritis Rheum. 1970, 13: 769-776. 10.1002/art.1780130606.CrossRefPubMed
32.
Sivakumar B, Akhavani MA, Winlove CP, Taylor PC, Paleolog EM, Kang N: Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am. 2008, 33: 49-58. 10.1016/j.jhsa.2007.09.002.CrossRefPubMed
33.
Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, Buggy D, Taylor CT, O'Sullivan J, Fearon U, Veale DJ: Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis. 2010, 69: 1389-1395. 10.1136/ard.2009.119776.PubMedCentralCrossRefPubMed
34.
Kennedy A, Ng CT, Chang TC, Biniecka M, O'Sullivan JN, Heffernan E, Fearon U, Veale DJ: Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum. 2011, 63: 923-932. 10.1002/art.30221.CrossRefPubMed
35.
Wang GL, Semenza GL: Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993, 268: 21513-21518.PubMed
36.
Gaber T, Schellmann S, Erekul KB, Fangradt M, Tykwinska K, Hahne M, Maschmeyer P, Wagegg M, Stahn C, Kolar P, Dziurla R, Lohning M, Burmester GR, Buttgereit F: Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia. J Immunol. 2011, 186: 764-774. 10.4049/jimmunol.0903421.CrossRefPubMed
37.
Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C, Tanaka H: TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol. 2005, 174: 7592-7599.CrossRefPubMed
38.
Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001, 44: 1540-1544. 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7.CrossRefPubMed
39.
Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS: HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003, 112: 645-657. 10.1016/S0092-8674(03)00154-5.PubMedCentralCrossRefPubMed
40.
van Hal TW, van Bon L, Radstake TR: A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis. Int J Rheumatol. 2011, 2011: 824972-PubMedCentralCrossRefPubMed
41.
Beyer C, Schett G, Gay S, Distler O, Distler JH: Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009, 11: 220-10.1186/ar2598.PubMedCentralCrossRefPubMed
42.
Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Muller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S: Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004, 95: 109-116. 10.1161/01.RES.0000134644.89917.96.CrossRefPubMed
43.
Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD: The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011, 12: 295-303.PubMedCentralCrossRefPubMed
44.
Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC: Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011, 186: 3299-3303. 10.4049/jimmunol.1003613.PubMedCentralCrossRefPubMed
45.
Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, Luo W, Zeller K, Shimoda L, Topalian SL, Semenza GL, Dang CV, Pardoll DM, Pan F: Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011, 146: 772-784. 10.1016/j.cell.2011.07.033.PubMedCentralCrossRefPubMed
46.
Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H: HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011, 208: 1367-1376. 10.1084/jem.20110278.PubMedCentralCrossRefPubMed
47.
Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ: IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One. 2011, 6: e24048-10.1371/journal.pone.0024048.PubMedCentralCrossRefPubMed
48.
Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A: Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res. 2008, 14: 5947-5952. 10.1158/1078-0432.CCR-08-0229.CrossRefPubMed
49.
Chang X, Wei C: Glycolysis and rheumatoid arthritis. Int J Rheum Dis. 2011, 14: 217-222. 10.1111/j.1756-185X.2011.01598.x.CrossRefPubMed
50.
Henderson B, Bitensky L, Chayen J: Glycolytic activity in human synovial lining cells in rheumatoid arthritis. Ann Rheum Dis. 1979, 38: 63-67. 10.1136/ard.38.1.63.PubMedCentralCrossRefPubMed
51.
Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C: Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 2003, 48: 944-954. 10.1002/art.10898.CrossRefPubMed
52.
Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999, 286: 1732-1735. 10.1126/science.286.5445.1732.CrossRefPubMed
53.
Fernandez D, Bonilla E, Mirza N, Niland B, Perl A: Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54: 2983-2988. 10.1002/art.22085.PubMedCentralCrossRefPubMed
54.
Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994, 37: 289-297. 10.1002/art.1780370219.CrossRefPubMed
55.
Fernandez D, Perl A: mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discov Med. 2010, 9: 173-178.PubMedCentralPubMed
56.
Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S: Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 2010, 62: 2476-2487. 10.1002/art.27498.CrossRefPubMed
57.
Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ: Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 2009, 60: 3821-3830. 10.1002/art.24986.PubMedCentralCrossRefPubMed
58.
Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, Zeng C, Zhao Y: The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+ T cells in mice. Transpl Immunol. 2007, 17: 153-161. 10.1016/j.trim.2007.01.002.CrossRefPubMed
59.
Ogino H, Nakamura K, Iwasa T, Ihara E, Akiho H, Motomura Y, Akahoshi K, Igarashi H, Kato M, Kotoh K, Ito T, Takayanagi R: Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. J Gastroenterol. 2011, 47: 366-376.CrossRefPubMed
60.
Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R: mTOR regulates memory CD8 T-cell differentiation. Nature. 2009, 460: 108-112. 10.1038/nature08155.PubMedCentralCrossRefPubMed
61.
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y: Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009, 460: 103-107. 10.1038/nature08097.PubMedCentralCrossRefPubMed
62.
Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, Cross JR, Jung E, Thompson CB, Jones RG, Pearce EJ: Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010, 115: 4742-4749. 10.1182/blood-2009-10-249540.PubMedCentralCrossRefPubMed
63.
Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS, Lee JY: Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology. 2010, 129: 516-524. 10.1111/j.1365-2567.2009.03203.x.PubMedCentralCrossRefPubMed
64.
Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P, Cascante M, Bosca L: Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol. 2010, 185: 605-614. 10.4049/jimmunol.0901698.CrossRefPubMed
65.
Garedew A, Moncada S: Mitochondrial dysfunction and HIF1alpha stabilization in inflammation. J Cell Sci. 2008, 121: 3468-3475. 10.1242/jcs.034660.CrossRefPubMed
66.
Roiniotis J, Dinh H, Masendycz P, Turner A, Elsegood CL, Scholz GM, Hamilton JA: Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with their maturation under aerobic conditions. J Immunol. 2009, 182: 7974-7981. 10.4049/jimmunol.0804216.CrossRefPubMed
67.
Hannah S, Mecklenburgh K, Rahman I, Bellingan GJ, Greening A, Haslett C, Chilvers ER: Hypoxia prolongs neutrophil survival in vitro. FEBS Lett. 1995, 372: 233-237. 10.1016/0014-5793(95)00986-J.CrossRefPubMed
68.
Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N, Chilvers ER: Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med. 2005, 201: 105-115. 10.1084/jem.20040624.PubMedCentralCrossRefPubMed
69.
Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011, 17: 179-188. 10.1038/nm.2279.PubMedCentralCrossRefPubMed
70.
Gergely P, Grossman C, Niland B, Puskas F, Neupane H, Allam F, Banki K, Phillips PE, Perl A: Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46: 175-190. 10.1002/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H.PubMedCentralCrossRefPubMed
71.
Pedersen-Lane JH, Zurier RB, Lawrence DA: Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol. 2007, 81: 934-941. 10.1189/jlb.0806533.CrossRefPubMed
72.
Shah D, Wanchu A, Bhatnagar A: Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology. 2011, 216: 1010-1017. 10.1016/j.imbio.2011.04.001.CrossRefPubMed
73.
Pedersen BK: Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun. 2011, 25: 811-816. 10.1016/j.bbi.2011.02.010.CrossRefPubMed
74.
Straub RH, Besedovsky HO: Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases. FASEB J. 2003, 17: 2176-2183. 10.1096/fj.03-0433hyp.CrossRefPubMed
75.
Williams GC: Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957, 11: 398-411. 10.2307/2406060.CrossRef
76.
Straub RH: [Neuroendocrine immunology: new pathogenetic aspects and clinical application]. Z Rheumatol. 2011, 70: 767-774. 10.1007/s00393-011-0784-8.CrossRefPubMed
77.
Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003, 348: 727-734. 10.1056/NEJMra020529.CrossRefPubMed
78.
Straub RH: Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases. Brain Behav Immun. 2011, 25: 1-5. 10.1016/j.bbi.2010.08.002.CrossRefPubMed
79.
Buttgereit F, Brand MD, Muller M: ConA induced changes in energy metabolism of rat thymocytes. Biosci Rep. 1992, 12: 381-386. 10.1007/BF01121501.CrossRefPubMed
80.
Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, Bennink JR, Yewdell JW: Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity. 2003, 18: 343-354. 10.1016/S1074-7613(03)00051-7.CrossRefPubMed
81.
Maravillas-Montero JL, Santos-Argumedo L: The myosin family: unconventional roles of actin-dependent molecular motors in immune cells. J Leukoc Biol. 2011, 91: 35-46.CrossRefPubMed
82.
83.
Sauer RT, Baker TA: AAA+ proteases: ATP-fueled machines of protein destruction. Annu Rev Biochem. 2011, 80: 587-612. 10.1146/annurev-biochem-060408-172623.CrossRefPubMed
84.
Procko E, Gaudet R: Antigen processing and presentation: TAPping into ABC transporters. Curr Opin Immunol. 2009, 21: 84-91. 10.1016/j.coi.2009.02.003.CrossRefPubMed
85.
Authier F, Posner BI, Bergeron JJ: Endosomal proteolysis of internalized proteins. FEBS Lett. 1996, 389: 55-60. 10.1016/0014-5793(96)00368-7.CrossRefPubMed
86.
Togashi K, Kataoka T, Nagai K: Characterization of a series of vacuolar type H+-ATPase inhibitors on CTL-mediated cytotoxicity. Immunol Lett. 1997, 55: 139-144. 10.1016/S0165-2478(97)02698-9.CrossRefPubMed
87.
White C, Lee J, Kambe T, Fritsche K, Petris MJ: A role for the ATP7A copper-transporting ATPase in macrophage bactericidal activity. J Biol Chem. 2009, 284: 33949-33956. 10.1074/jbc.M109.070201.PubMedCentralCrossRefPubMed
88.
Marques-da-Silva C, Chaves MM, Rodrigues JC, Corte-Real S, Coutinho-Silva R, Persechini PM: Differential modulation of ATP-induced P2X7-associated permeabilities to cations and anions of macrophages by infection with Leishmania amazonensis. PLoS One. 2011, 6: e25356-10.1371/journal.pone.0025356.PubMedCentralCrossRefPubMed
89.
Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, Ricordi C, Westendorf AM, Grassi F: ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal. 2011, 4: ra12-10.1126/scisignal.2001270.CrossRefPubMed
90.
Straub RH: Evolutionary medicine and chronic inflammatory state-known and new concepts in pathophysiology. J Mol Med (Berl). 2012, 90: 523-534. 10.1007/s00109-012-0861-8.CrossRef
Metadata
Title
Energy metabolism and rheumatic diseases: from cell to organism
Authors
Cornelia M Spies
Rainer H Straub
Frank Buttgereit
Publication date
01-06-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3885

Other articles of this Issue 3/2012

Arthritis Research & Therapy 3/2012 Go to the issue

Research article

ERAP1 genetic variations associated with HLA-B27 interaction and disease severity of syndesmophytes formation in Taiwanese ankylosing spondylitis

Research article

RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis

Research article

CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts

Research article

Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals

Research article

Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis

Editorial

The interaction of canonical bone morphogenetic protein- and Wnt-signaling pathways may play an important role in regulating cartilage degradation in osteoarthritis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits